Objective
CHARACTERIZIATION AND UTILISATION OF TWO NEW FILARIAL MODELS FOR INVESTIGATIONS OF IMMUNITY CHEMOTHERAPY AND PATHOLGY. THIS WORK IS CONCERNED WITH PREVENTION AND TREATMENT OF FILARIAL INFECTIONS AND IN PARTICULAR ANCHOCERIAS. ATTENTION WILL FOCUS ON THE INTERPLAY BETWEEN IMMUNITY, PATHOLOGY AND DRUG TREATMENT AND N PARTICULAR IVERMECETIN. KNOWLEDGE IN THIS AREA WILL BE IMPORTANT FOR THE SUCCESSFUL DEVELOPMENT AND USE OF A VACCINE. FOR THIS WORK TWO MURID MODELS WILL BE USED. FIRST LITOMOSOIDEDS SIGMODONTIS (STRAN PARIS) WHCIH CAN UDERGO COMPLETE CYCLICAL DEVELOPMENT IN IMMUUNICOMPENT MICE (MUSMUSCULUS) AND PROVIDES AN EXCELLENT OPPORTUNITY TO INVESTIGATE CELLULAR (AND HUMORAL) RESPONSES EVOKED BY A FILARIAL PARASITE IN THE BEST IMMUNOLOGICALLY CHARACTERIZED OF MAMMALIAN HOSTS. SECOND MONANEMA MARTINI WHICH PRESENTS WITH DERMAL MICROFILARIAE AND INDUCES OCULAR AND SKIN PATHOLOGY SIMILAR TO THAT SEEN IN HUMAN ONCHOCERCIASIS. THE OBJECTIVES ARE FURTHER PARASITOLIGAL CHARACTERIZATION OF THE FOLLOWING FILARIAL MODELS: L SINGMODONTIS IN MICE AND MERIONES AND M MARTINI IN LEMNISCOMY STRIATUS AND MERIONES. ASSESSMENT OF CELLULAR RESPONSES EVOKED BY L SIGMODONTIS IMMUNCOMPENTET MICE MUSMUSCULUS AND FOLLOWING VACCINATION WITH IRRADIATED IARVAE AND RECOMBINANT ANTIGENS. THIS INCLUDES AND INVESTIGATION OF THE ROLE OF THI AND TH2 T-HELPER CELL SUBSETS AND SELECTED CYCTOKINES. ASSESMENT OF THE EFFECT OF IVERMECTIN TREATMENT ON IMMUNE RESPONSE EVOKED BY L SIGMODONTIS AND M MARTINI. INCLUDING AN INVESTIGATION OF DRUG INDUCED IMMUNITY WHICH HAD BEEN OBSERVED TO FOLLOW IVERMECTIN TREATMENT IN MAN AND RODENT MODELS. THE PHARMACOKINETICS OF IVERMECITIN IN DIFFERENT RODENT MODELS WILL BE EXAMINED BEFORE AND AFTER INFECTION AND IMMUNIZATION. IDENTIFICATION OF POSSIBLE CORRELATIONS BETWEEN PARASITOLIGICAL FEATURES, DRUGS, IMMUNITY AND PATHOLOGY. THE TECHNIQUES PROCEDURES AND PERSONAL EXPERTISE REQUIRED EXIST IN THE LABOROTORIES OF THE FOUR PARTNERS. THIS PROGRAMME COMPLEMENTS OTHER COLLABORATIONS INCLUDING HUMAN FIELD STUDIES.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology immunisation
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pathology
- medical and health sciences basic medicine pharmacology and pharmacy pharmacokinetics
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
75231 Paris
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.